Corcept Therapeutics Reports 7% Revenue Increase Amid Legal Risks

Corcept Therapeutics reported a 7% year-over-year increase in Q1 2025 revenue to $157.2 million, reflecting a strong market presence and effective commercialization strategies. Despite this revenue growth, net income declined to $20.5 million, primarily due to increased investments in research and development as well as selling, general, and administrative expenses, highlighting the company's focus on expanding its future product pipeline. Analysts remain optimistic about Corcept's growth prospects, particularly in anticipation of potential FDA approval for its drug relacorilant, with several forecasting a significant upside in share price. However, there is a divergence among valuation models: while brokerage firms rate the stock as 'Outperform' with high price targets, GuruFocus estimates a potential downside based on its own fair value calculations. The company is also preparing to expand its sales force in anticipation of new product launches. Overall, investor sentiment is mixed, balancing optimism for future growth against concerns about rising expenses and valuation discrepancies.